The Wyss Center and Artiria Medical have collaborated to expedite the development of a technology that can potentially lower mortality and enhance the quality of life in stroke patients.
The third major cause of disability globally, stroke can lead to bleeding in the brain.
This type of haemorrhagic stroke can cause an uncontrolled contraction of brain arteries called severe cerebral vasospasm, where entire brain regions become blood-deprived in the subsequent days, leading to severe consequences.
Developed by medical device company Artiria, the new technology can potentially aid in preventing arterial constriction after a haemorrhagic stroke.
Using a less-invasive electroactive endovascular probe, the technology interacts with some nerves from within the arteries in the lower brain for releasing arterial constriction in the entire brain.
The technology, which is based on the company’s endovascular platform, is centred around a biocompatible expandable system. This approach facilitates the safe delivery of electrical energy into the targeted arteries using flexible thin-film electrodes.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Wyss Center noted that the partners’ merged capabilities in electrode development will allow enhancement of the device’s ability to accurately control the treatment.
Artiria Medical CEO Guillaume Petit-Pierre said: “There is currently no truly effective solution that can treat cerebral vasospasm following haemorrhagic stroke, yet we know this is a leading cause of disability and death.
“We believe our technology has the potential to bring a new standard of care to patients and dramatically improve quality of life after stroke.”
The Swiss Innovation Agency, Innosuisse, extended support for the team to analyse and validate the therapy’s effectiveness in pre-clinical studies, in a bid to initiate trials in humans.
Wyss Center CEO Mary Tolikas said: “Collaborating with driven entrepreneurs like the Artiria team is key to our mission to translate neuroscience innovations into clinical solutions.”
At present, drugs or angioplasty to dilate the arteries with a balloon are the therapies available for cerebral vasospasm. These treatments have complications, such as the risk of further bleeding.